Claims for Patent: 6,083,523

Summary for Patent: 6,083,523

Title:	Implantable biocompatable immunoisolatory vehicle for delivery of selected therapeutic products
Abstract:	An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual.
Inventor(s):	Dionne; Keith E. (Rehoboth, MA), Emerich; Dwaine F. (Providence, RI), Hoffman; Diane (Cambridge, MA), Sanberg; Paul R. (Spring Hill, FL), Christenson; Lisa (New Haven, CT), Hegre; Orion D. (Green Valley, AZ), Scharp; David W. (St. Louis, MO), Lacy; Paul E. (Webster Grove, MO), Aebischer; Patrick (Lutry, CH), Vasconcellos; Alfred V. (Cranston, RI), Lysaght; Michael J. (Greenwich, RI), Gentile; Frank T. (Warwich, RI)
Assignee:	Brown University Research Foundation (Providence, RI) Brown University (Providence, RI)
Application Number:	09/148,671
Patent Claims:	1. An implantable immunoisolatory vehicle for providing a biologically active product or function to an individual, the immunoisolatory vehicle comprising: (a) a core comprising a volume in excess of 1 .mu.l and at least 10.sup.4 living cells dispersed in a biocompatible liquid, said cells being capable of secreting a selected biologically active product or of providing a selected biological function to an individual; and (b) an external permselective jacket surrounding said core, said jacket being greater than 5 microns thick and formed from a hydrogel that does not tonically bond to a polymer of opposite charge on the core during formation of the jacket, said jacket being free of said cells projecting, externally therefrom, said jacket being biocompatible and having a molecular weight cutoff permitting passage of molecules to and from the core through said jacket to provide said biologically active product or function. 2. The immunoisolatory vehicle of claim 1 in which said hydrogel comprises alginate cross-linked with a multivalent ion. 3. The immunoisolatory vehicle of claim 1 wherein said vehicle is of sufficient size and durability for retrieval after implantation. 4. The immunoisolatory vehicle of claim 1 in which said cells are selected from the group consisting of insulin-producing cells, adrenal chromaffin cells, antibody-secreting cells, fibroblasts, astrocytes, Beta cell lines, and Chinese hamster ovary cells. 5. The immunoisolatory vehicle of claim 1 in which the cells are derived from a cell bank. 6. The immunoisolatory vehicle of claim 1 in which the interface between said core and jacket are free of an intermediate layer of fibrogenic material linking said core and jacket. 7. An immunoisolatory vehicle for providing a biologically active product or function to an individual, the immunoisolatory vehicle comprising: (a) a core comprising a volume in excess of 1 .mu.l and at least 10.sup.4 living cells dispersed in a biocompatible liquid, said cells being capable of secreting biologically active product or of providing a biological function to an individual; and (b) an external permselective jacket surrounding said core, said jacket comprising a biocompatible thermoplastic, said jacket being immunoisolatory and having a molecular weight cutoff permitting passage of molecules to and from the core through said jacket to provide said biological product or function. 8. The immunoisolatory vehicle of claim 7 in which said cells are selected from the group consisting of insulin-producing cells, adrenal chromaffin cells, antibody-secreting cells, fibroblasts, astrocytes, Beta cell lines, and Chinese hamster ovary cells. 9. The immunoisolatory vehicle of claim 7 in which said jacket is formed of a hydrogel material. 10. The immunoisolatory vehicle of claim 7 in which the interface between said core and jacket is free of an intermediate layer of fibrogenic material linking said core and jacket. 11. The immunoisolatory vehicle of claim 7 in which said core and said external jacket form an interface substantially free of direct ionic bonding. 12. The immunoisolatory vehicle of claim 7 in which said external jacket is a non-spherical shape. 13. The immunoisolatory vehicle of claim 7 in which said molecular weight cutoff is above about 100 kD. 14. The immunoisolatory vehicle of claim 7 in which said cells are formed by aggregating naturally occurring individual cells or cell clusters into an improved diffusional aggregate form adapted for increased packing per unit volume. 15. The immunoisolatory vehicle of claim 7 in which said cell clusters are selected from the group consisting of pancreatic islets, adrenal chromaffin cells and insulin secreting cell lines. 16. The immunoisolatory vehicle of claim 7 in which said jacket is formed of a hydrogel material. 17. The implantable vehicle of claim 7 wherein said cells secrete nerve growth factor. 18. The immunoisolatory vehicle of claims 1 or 7 wherein said vehicle is a flat sheet. 19. The immunoisolatory vehicle of claims 1 or 7 wherein said external jacket is in substantially flat or tubular form. 20. The immunoisolatory vehicle of claims 1 or 7 wherein said cells are allogeneic to said individual. 21. The immunoisolatory vehicle of claims 1 or 7 wherein said cells secrete antibodies. 22. The immunoisolatory vehicle of claims 1 or 7 wherein the biologically active product is an analgesic or pain-reducing substance. 23. The immunoisolatory vehicle of claims 1 or 7, wherein said cells are capable of secreting a biologically active product selected from the group consisting of growth factor, trophic factor, or both. 24. The immunoisolatory vehicle of claim 7, wherein said cells comprise cells from a cell bank. 25. The immunoisolatory vehicle of claims 1 or 7, wherein said cells are derived from a pathogen free animal. 26. The immunoisolatory vehicle of claims 1 or 7, wherein said jacket further comprises a hydrophilic or hydrophobic additive. 27. The immunoisolatory vehicle of claims 1 or 7, wherein said biologically active product is selected from the group consisting of enkephalins, catecholamines, opioid peptides, and mixtures thereof. 28. The immunoisolatory vehicle of claims 1 or 7, wherein said biologically active product is selected from the group consisting of antibodies, enzymes, trophic factors, growth factors, hormones and biological response modifiers. 29. The immunoisolatory vehicle of claim 28, wherein said biologically active product is a cytokine or lymphokine. 30. The immunoisolatory vehicle of claims 1 or 7, wherein said biologically active product is a neurotransmitter. 31. The immunoisolatory vehicle of claim 24, wherein said neurotransmitter is selected from the group consisting of dopamine, L-dopa, gamma aminobutyric acid, serotonin, acetylcholine, noradrenaline, epinephrine and glutamic acid. 32. The immunoisolatory vehicle of claims 1 or 7, wherein said biologically active product is dopamine. 33. The immunoisolatory vehicle of claims 1 or 7, wherein said biologically active product is selected from the group consisting of nerve growth factor, basic fibroblast growth factor, ciliary neurotrophic factor, brain-derived neurotrophic factor, glial-derived neurotrophic factor, neurotrophin-3, platelet derived growth factor, epidermal growth factor, neurotensin and Substance P. 34. The immunoisolatory vehicle of claims 1 or 7, wherein said biologically active product is insulin, parathyroid hormone, interleukin 3, erythropoietin, albumin, transferrin or Factor VIII. 35. The immunoisolatory vehicle of claims 1 or 7, wherein accessory cells are co-isolated with the cells in said core. 36. The immunoisolatory vehicle of claims 1 or 7, wherein said cells are adrenal chromaffin cells. 37. The immunoisolatory vehicle of claims 1 or 7, wherein said molecular weight cutoff is between 50-2000 kD. 38. The immunoisolatory vehicle of claims 1 or 7, wherein said jacket is between about 10 and 200 microns thick. 39. The immunoisolatory vehicle of claims 1 or 7, wherein said liquid comprises a nutrient medium. 40. The immunoisolatory vehicle of claim 39, wherein said liquid further comprises fetal bovine serum or equine serum.

Details for Patent 6,083,523

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2011-04-25